Emerging Antitrust Issues—Implications to the Life Sciences Industry
Allegations of antitrust violations, particularly in the life sciences industry, have become more prevalent in recent years. In addition to cases brought by private litigants, the Food and Drug Administration and the Federal Trade Commission (FTC) are working together to prevent anticompetitive business practices. Mergers and acquisitions among pharmaceutical companies, as well as their conduct with regard to the expiration of their drug patents, have been closely monitored by the FTC.
In this webcast, Edgeworth Partner Dr. George Korenko will join other thought leaders to present on antitrust litigation and regulatory trends, their implications on the life sciences industry, and best practices for compliance.
- Learn more and register here.